The most read scientific articles of november

November’s Most Read Studies in Interventional Cardiology in solaci.org

01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of >3 cm aortic diameter.  They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures.  Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since<a href="https://solaci.org/en/2021/12/06/novembers-most-read-studies-in-interventional-cardiology-in-solaci-org/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

AFIRE Study | Hidden Risks After Bleeding in Coronary Disease and Atrial Fibrillation

Patients with atrial fibrillation (AF) and stable coronary disease who suffer from major bleeding present an extremely high risk of subsequent cardiovascular events. Preventing bleeding is necessary, and so is preventing the risk of subsequent cardiovascular events and death. The association between coronary angioplasty, early bleeding, and an increase in death and infarction rates after<a href="https://solaci.org/en/2021/12/01/afire-study-hidden-risks-after-bleeding-in-coronary-disease-and-atrial-fibrillation/" title="Read more" >...</a>

TCT 2021 | STOPDAPT-2 y MASTER-DAPT: la discusión continúa del ESC al TCT

TCT 2021 | STOPDAPT-2 and MASTER-DAPT: The Conversation Continues from ESC to TCT

Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct-2/" title="Read more" >...</a>

TCT 2021 | STOPDAPT-2 and MASTER-DAPT: The Conversation Continues from ESC to TCT

Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the<a href="https://solaci.org/en/2021/11/12/tct-2021-stopdapt-2-and-master-dapt-the-conversation-continues-from-esc-to-tct/" title="Read more" >...</a>

TCT 2021 | FAVOR III: FFR derivado de la angiografía. Una herramienta que ahorra eventos

TCT 2021 | FAVOR III: Angiography-Derived FFR: An Event-Prevention Tool

Compared with visual estimation of lesions, using quantitative angiography-derived fractional flow reserve (quantitative flow ration, QFR) provides better clinical outcomes at one year for angioplasty. These results emerge from the Chinese FAVOR III study, presented at the 2021 TCT scientific sessions and simultaneously published in The Lancet. The simplicity and safety offered by QRF—since there is<a href="https://solaci.org/en/2021/11/10/tct-2021-favor-iii-ffr-derivado-de-la-angiografia-una-herramienta-que-ahorra-eventos-2/" title="Read more" >...</a>

TCT 2021 | FAME 3: Sorpresas en un estudio largamente esperado

TCT 2021 | FAME 3: Surprises in a Long-Awaited Study

Angioplasty could not reach non-inferiority to surgery to treat patients with three-vessel lesions. In this head-to-head study of both revascularization strategies in patients with three-vessel coronary disease, fractional flow reserve (FFR)-guided angioplasty could not reach the performance of myocardial revascularization surgery in relation to a composite of adverse events. The FAME 3 study was presented during<a href="https://solaci.org/en/2021/11/10/tct-2021-fame-3-surprises-in-a-long-awaited-study/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?

Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) will benefit from rivaroxaban monotherapy both in terms of safety and efficacy. The AFIRE study included 2215 patients with atrial fibrillation and stable coronary artery disease (CAD). A subgroups analysis recently published in JACC Intv evaluated patients undergoing coronary stenting.  The study compared rivaroxaban + antiplatelet<a href="https://solaci.org/en/2021/11/04/afire-trial-atrial-fibrillation-and-pci-what-is-the-ideal-therapy/" title="Read more" >...</a>

ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality

The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Now, this new analysis suggests that anatomic severity can predict events. However (surprisingly, once more), altering this severity through angioplasty does not change the prognosis<a href="https://solaci.org/en/2021/11/01/ischemia-prognosis-is-determined-by-anatomy-not-functionality/" title="Read more" >...</a>

The most read scientific papers of September in interventional cardiology

01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>

SOLACI-CACI 2021 | Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm Session

✔️ Watch again the Session on “Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm” in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: SESSION I: Chronic Thromboembolic Pulmonary Hypertension 02:48 – Definition, epidemiology, diagnostic algorithm and pharmacological treatment. – Pedro Trujillo 16:27 – Invasive Endovascular Strategies in Chronic PTE: Pulmonary Angioplasty – Fabio Solano 30:13 – Surgical Thromboendarterectomy.<a href="https://solaci.org/en/2021/09/21/solaci-caci-2021-complex-pulmonary-hypertension-and-aortic-endovascular-aneurysm-session-2/" title="Read more" >...</a>